Cellular stress increases the probability of developing autoimmune diseases

June 13, 2017

A team of researchers led by Marc Veldhoen, Instituto de Medicina Molecular (iMM), Lisboa, have found that cellular stress enhances the activation of certain type of immune cells implicated in many chronic inflammatory conditions, increasing the risk of autoimmune diseases.

T cells, a type of white blood cell, can be tuned into different activation modes thereby tailoring immune responses to adequately deal with infections. However, some of these activation modes can particularly contribute to autoimmune diseases such as arthritis, diabetes and multiple sclerosis.

The Veldhoen lab has been studying T cell activation modes for many years and had already noticed that one particular activation status, termed Th17, is much more robust than other states leading researchers to hypothesize that these cells are more resistant to adverse conditions than other T cell counterparts.

By controlling external conditions such as osmotic pressure and sugar concentration in the culture medium as well as oxygen pressure, the team revealed that Th17 cells are preferentially generated under adverse conditions when compared to optimal conditions. Moreover, by using mouse models of autoimmunity Veldhoen and colleagues demonstrated that if cell stress was inhibited, lower numbers of Th17 cells were generated and the animals had reduced disease symptoms.

There has been an increasing focus from both academia and pharmaceutical companies over the past years on Th17 cells, since they are implicated in several chronic inflammatory conditions. In fact, studies interfering with the biology of these cells have shown promise for therapeutic applications in psoriasis and arthritis, for example.

These novel findings offer additional pharmacological targets to reduce cellular stress at sites of inflammation by reducing Th17 generation and preserving other T cell responses which may hold important clinical implications.

The study "Cellular stress in context of an inflammatory environment supports TGFβ independent T helper-17 differentiation" was published in Cell Reports.
-end-
Instituto de Medicina Molecular Lisboa (iMM Lisboa)

The iMM Lisboa - Instituto de Medicina Molecular is a leading Portuguese private non-profit research institute that offers a vibrant scientific environment, aiming to nurture innovative ideias in basic, clinical and translational biomedical research. Created in 2002, iMM Lisboa has established itself as a major national and internationally competitive biomedical institute. Its strategy has been defined by promotion of excellence, leveraged by high-quality human resources, increasing expenditure in infrastructures and knowledge transfer to the society. iMM Lisboa is an inclusive, equal opportunity employer offering attractive conditions and benefits.

Instituto de Medicina Molecular

Related Arthritis Articles from Brightsurf:

Physical activity and sleep in adults with arthritis
A new study published in Arthritis Care & Research has examined patterns of 24-hour physical activity and sleep among patients with rheumatoid arthritis, lupus, and knee osteoarthritis.

Is rheumatoid arthritis two different diseases?
While disease activity improves over time for most rheumatoid arthritis (RA) patients, long-term outcomes only improve in RA patients with autoantibodies, according to a new study published this week in PLOS Medicine by Xanthe Matthijssen of Leiden University Medical Center, Netherlands, and colleagues.

Does the Mediterranean diet protect against rheumatoid arthritis?
Previous research has demonstrated a variety of health benefits associated with the Mediterranean diet, which is rich in olive oil, cereals, fruit and vegetables, fish, and a moderate amount of dairy, meat, and wine.

Reducing corticosteroid use in rheumatoid arthritis
Is the long-term use of glucocorticoids essential in people with chronic inflammatory diseases such as rheumatoid arthritis, or can early discontinuation prevent characteristic side effects?

Psoriasis onset determines if psoriatic arthritis patients develop arthritis or psoriasis first
In a new study presented at the 2019 ACR/ARP Annual Meeting, researchers found the age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis.

The ACR and the Arthritis Foundation present new guidelines offering therapeutic approaches and treatment options for juvenile idiopathic arthritis
Today, the American College of Rheumatology (ACR), in partnership with the Arthritis Foundation (AF), released two guidelines on juvenile idiopathic arthritis (JIA).

Does alcohol consumption have an effect on arthritis?
Several previous studies have demonstrated that moderate alcohol consumption is linked with less severe disease and better quality of life in patients with rheumatoid arthritis, but a new Arthritis Care & Research study suggests that this might not be because drinking alcohol is beneficial.

Prospect of a new treatment for rheumatoid arthritis
An international research group led by Charité -- Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.

Can rare lymphocytes combat rheumatoid arthritis?
Immunologists at Friedrich-Alexander-Universität Erlangen-Nürnberg have demonstrated that ILC2, a group of rare lymphoid cells, play a key role in the development of inflammatory arthritis.

Which pain medication is safest for arthritis patients?
In a recent Alimentary Pharmacology & Therapeutics study, arthritis patients taking nonsteroidal anti-inflammatory drugs (NSAIDs) for pain plus a stomach acid-reducing medicine called esomeprazole had infrequent gastrointestinal side effects.

Read More: Arthritis News and Arthritis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.